115 related articles for article (PubMed ID: 1707336)
1. Successful reinduction therapy with amsacrine and cyclocytidine in acute nonlymphoblastic leukemia in children. A report from the Childrens Cancer Study Group.
Miller LP; Pyesmany AF; Wolff LJ; Rogers PC; Siegel SE; Wells RJ; Buckley JD; Hammond GD
Cancer; 1991 May; 67(9):2235-40. PubMed ID: 1707336
[TBL] [Abstract][Full Text] [Related]
2. Effective reinduction therapy for childhood acute nonlymphoid leukemia using simultaneous continuous infusions of teniposide and amsacrine.
Mirro J; Kalwinsky DK; Grier HE; Santana VM; Mason C; Murphy SB; Dahl GV
Cancer Chemother Pharmacol; 1989; 24(2):123-7. PubMed ID: 2731312
[TBL] [Abstract][Full Text] [Related]
3. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogenous leukemia (AML).
Jehn U; Heinemann V; Wilmanns W
Anticancer Res; 1989; 9(1):119-24. PubMed ID: 2705739
[TBL] [Abstract][Full Text] [Related]
4. [Combined therapy with AMSA and etoposide (VP 16-213) in refractory acute myeloid leukemia. A phase I study].
Hiddemann W; Achterrath W; Urbanitz D; Preusser P; Balleisen L; Kirchhof B; Stenzinger W; Büchner T
Onkologie; 1984 Aug; 7(4):214-6. PubMed ID: 6384864
[TBL] [Abstract][Full Text] [Related]
5. Toxicity trials of amsacrine (AMSA) and etoposide +/- azacitidine (AZ) in childhood acute non-lymphocytic leukemia (ANLL): a pilot study.
Steuber CP; Holbrook T; Camitta B; Land VJ; Sexauer C; Krischer J
Invest New Drugs; 1991 May; 9(2):181-4. PubMed ID: 1714886
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and clinical cross-resistance of a new combination therapy (AMSA/VP16) in previously treated patients with acute nonlymphocytic leukemia.
Tschopp L; von Fliedner VE; Sauter C; Maurice P; Gratwohl A; Fopp M; Cavalli F
J Clin Oncol; 1986 Mar; 4(3):318-24. PubMed ID: 3456425
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of cyclocytidine in reinduction and maintenance therapy of children with acute nonlymphocytic leukemia previously treated with cytosine arabinoside: a report from Children's Cancer Study Group.
Movassaghi N; Higgins G; Pyesmany A; Baehner R; Chard R; Sather H; Hammond D
Med Pediatr Oncol; 1984; 12(5):352-6. PubMed ID: 6208468
[TBL] [Abstract][Full Text] [Related]
8. [AMSA/etoposide (VP 16-213). A phase I/II study in refractory acute myeloid leukemia].
Hiddemann W; Achterrath W; Urbanitz D; Preusser P; Balleisen L; Büchner T
Onkologie; 1985 Jun; 8(3):181-4. PubMed ID: 3895100
[TBL] [Abstract][Full Text] [Related]
9. [Intensification chemotherapy followed by allogenieic and autologous bone marrow transplantation in acute non-lymphoblastic leukemia in children].
Ortega Aramburu JJ; Olivé Oliveras T; Javier Manchón G; Bastida Vila P; Sánchez C; Giralt López J
Sangre (Barc); 1991 Feb; 36(1):7-14. PubMed ID: 1853274
[TBL] [Abstract][Full Text] [Related]
10. Effective remission induction in children with recurrent acute myeloid leukemia by mAMSA, Ara-C, and VP 16.
Berthold F; Creutzig U; Lampert F
Haematol Blood Transfus; 1987; 30():406-9. PubMed ID: 3476374
[TBL] [Abstract][Full Text] [Related]
11. Therapy of refractory or recurrent childhood acute myeloid leukemia using amsacrine and etoposide with or without azacitidine: a Pediatric Oncology Group randomized phase II study.
Steuber CP; Krischer J; Holbrook T; Camitta B; Land V; Sexauer C; Mahoney D; Weinstein H
J Clin Oncol; 1996 May; 14(5):1521-5. PubMed ID: 8622066
[TBL] [Abstract][Full Text] [Related]
12. Early intensification of chemotherapy for childhood acute nonlymphoblastic leukemia: improved remission induction with a five-drug regimen including etoposide.
Kalwinsky D; Mirro J; Schell M; Behm F; Mason C; Dahl GV
J Clin Oncol; 1988 Jul; 6(7):1134-43. PubMed ID: 3292713
[TBL] [Abstract][Full Text] [Related]
13. Treatment of refractory acute myeloid leukemia with mAMSA and VP 16-213 in combination: results of a clinical phase I/II study.
Hiddemann W; Urbanitz D; Preusser P; Achterrath W; Büchner T
Hematol Oncol; 1989; 7(4):267-73. PubMed ID: 2737607
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of recurrence of acute myeloid leukemia in childhood. A retrospective analysis of recurrence in the AML-BFM-83 study].
Stahnke K; Ritter J; Schellong G; Beck JD; Kabisch H; Lampert F; Creutzig U
Klin Padiatr; 1992; 204(4):253-7. PubMed ID: 1518261
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy for relapsed and resistant acute nonlymphoblastic leukemia. Effect of ATA, an amsacrine-containing regime.
Liang R; Chan TK; Todd D
Cancer Chemother Pharmacol; 1988; 21(1):68-70. PubMed ID: 3342467
[TBL] [Abstract][Full Text] [Related]
16. Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol.
Berman E; Arlin ZA; Gaynor J; Miller W; Gee T; Kempin SJ; Mertelsmann R; Andreeff M; Reich L; Nahmias N
Leukemia; 1989 Feb; 3(2):115-21. PubMed ID: 2911205
[TBL] [Abstract][Full Text] [Related]
17. 4'-(9-Acridinylamino) methanesulfon-m-anisidide (AMSA): a new drug effective in the treatment of adult acute leukemia.
Legha SS; Keating MJ; Zander AR; McCredie KB; Bodey GP; Freireich EJ
Ann Intern Med; 1980 Jul; 93(1):17-21. PubMed ID: 6930826
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
Sung WJ; Kim DH; Sohn SK; Kim JG; Baek JH; Jeon SB; Moon JH; Ahn BM; Lee KB
Jpn J Clin Oncol; 2005 Oct; 35(10):612-6. PubMed ID: 16172175
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial of amsacrine and rubidazone in 39 patients with acute promyelocytic leukemia.
Fenaux P; Tertian G; Castaigne S; Tilly H; Leverger G; Guy H; Bordessoule D; Leblay R; Le Gall E; Colombat P
J Clin Oncol; 1991 Sep; 9(9):1556-61. PubMed ID: 1805818
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of cyclocytidine in children with advanced acute leukemia and solid tumors.
Finklestein JZ; Higgins G; Krivit W; Hammond D
Cancer Treat Rep; 1979 Aug; 63(8):1331-3. PubMed ID: 89907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
